Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PricewaterhouseCoopers
Pharma
2022 forecast: After a slow 2021, will biopharma M&A tick up?
2022 could be a “pretty buoyant year” for biopharma M&A, and not just because large companies have accumulated plenty of cash, PwC said.
Angus Liu
Dec 22, 2021 9:55am
Pharma ESG efforts skew social, PwC study finds
Aug 19, 2021 9:30am
Biopharma M&A on track for a strong second half: analysts
Jun 28, 2021 10:05am
M&A poised to rebound, fueled by pharma's $1.47T war chest
Dec 22, 2020 3:00am
Pharma deal values plummet 56% due to COVID-19: report
Jul 23, 2020 3:30pm
Pharma should rewrite marketing playbook in 2020: expert
Jan 23, 2020 8:30am
